You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

transformed DLBCL

Showing 1 - 25 of 736
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL) Trial in Baltimore

Completed
Has Results
  • CD20+, B-cell Lymphomas
  • +5 more
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oct 4, 2021

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Camrelizumab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 10, 2021

Non-GCB/ABC DLBCL, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (PD-1 Antibody, Lenalidomide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

Withdrawn
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in United States

Recruiting
  • Relapsed/Refractory B-cell Lymphomas
  • +11 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
Jul 26, 2022

Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) Trial in Seoul (CRC01,

Recruiting
  • Relapsed Large B-cell Lymphoma
  • +5 more
  • CRC01
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
Apr 29, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2) Trial in Worldwide

Completed
  • B-cell Lymphomas (Phase 1)
  • +5 more
  • Birmingham, Alabama
  • +51 more
Dec 8, 2021

Hematological Malignancies - SANGUINE

Recruiting
  • Hematologic Malignancy
  • Blood sampling for HemaChip screening/diagnostic testing
  • Bone marrow sampling
  • Olomouc, Czechia
  • +3 more
Feb 9, 2023

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Hematologic Cancer Trial in Israel, United States (ABBV-101)

Not yet recruiting
  • Hematologic Cancer
  • Lone Tree, Colorado
  • +7 more
Feb 22, 2023

Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Dec 12, 2022

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)

Recruiting
  • Diffuse Large-cell B-cell Lymphoma
  • plamotamab
  • +2 more
  • Seattle, Washington
    Swedish Cancer Center
May 2, 2022

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,

Active, not recruiting
  • Adult Diffuse Large Cell Lymphoma
  • +2 more
  • DPX-Survivac
  • +2 more
  • Calgary, Alberta, Canada
  • +5 more
Nov 9, 2022

Diffuse Large B-cell Lymphoma Trial in Worldwide (Epcoritamab, Investigator's Choice Chemotherapy)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Epcoritamab
  • Investigator's Choice Chemotherapy
  • Irvine, California
  • +254 more
Jan 9, 2023

Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL) Trial in

Recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • +5 more
  • WZTL002-1 (1928T2z CAR-T cells)
  • Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
  • Wellington, New Zealand
    Wellington Hospital, Capital & Coast District Health Board
Feb 18, 2020

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)

Terminated
Has Results
  • AML Including AML de Novo and AML Secondary to MDS
  • DLBCL
  • Birabresib Dose 20 mg
  • (no location specified)
Aug 23, 2022

Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma Trial in Worldwide (Pixantrone +

Completed
Has Results
  • Diffuse Large B-cell Lymphoma
  • +3 more
  • Pixantrone + Rituximab
  • Gemcitabine + Rituximab
  • Tucson, Arizona
  • +130 more
Oct 21, 2021

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023